

Raffaella Giavazzi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/119565/raffaella-giavazzi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

8,037
citations

47
h-index

83
g-index

180
ext. papers

8,596
ext. citations

6.7
avg, IF

5.21
L-index

#	Paper	IF	Citations
167	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 186	22.4	2
166	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. <i>Matrix Biology</i> , 2021 , 103-104, 22-36	11.4	0
165	The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions. <i>Oncogene</i> , 2021 , 40, 1721-1736	9.2	5
164	A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data. <i>GigaScience</i> , 2020 , 9,	7.6	1
163	Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. <i>Cancers</i> , 2020 , 12,	6.6	3
162	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. <i>Cancers</i> , 2020 , 12,	6.6	1
161	A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. <i>ELife</i> , 2019 , 8,	8.9	24
160	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. <i>Carcinogenesis</i> , 2019 , 40, 303-312	4.6	22
159	Anti-angiogenesis for cancer: Current status and prospects. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S3-S6	8.2	11
158	Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018 , 143, 2187-2199	7.5	7
157	Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. <i>Oncotarget</i> , 2018 , 9, 24707-24717	3.3	12
156	Drug-Homogeneity Index in Mass-Spectrometry Imaging. <i>Analytical Chemistry</i> , 2018 , 90, 13257-13264	7.8	5
155	Soluble stroma-related biomarkers of pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	30
154	Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. <i>Analytica Chimica Acta</i> , 2018 , 1042, 1-10	6.6	7
153	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. <i>Angiogenesis</i> , 2017 , 20, 233-241	10.6	17
152	Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer. <i>Cancer Research</i> , 2017 , 77, 6759-6769	10.1	4
151	Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. <i>Chinese Journal of Cancer</i> , 2016 , 35, 61		25

150	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 125-35	6.1	47
149	Orthotopic Model of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2016 , 1464, 139-149	1.4	5
148	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. <i>Scientific Reports</i> , 2016 , 6, 39284	4.9	47
147	Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. <i>Oncogene</i> , 2016 , 35, 6212-6222	9.2	22
146	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 647-58	4.7	13
145	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 73-81	4.5	32
144	Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. <i>International Journal of Cancer</i> , 2015 , 136, 721-9	7.5	39
143	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. <i>Oncotarget</i> , 2015 , 6, 3043-54	3.3	30
142	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. <i>Oncotarget</i> , 2015 , 6, 28389-400	3.3	12
141	Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. <i>American Journal of Pathology</i> , 2014 , 184, 1050-1061	5.8	45
140	Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. <i>Cancer Research</i> , 2014 , 74, 6980-90	10.1	89
139	Syngeneic murine metastasis models: B16 melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1070, 131-40	1.4	20
138	Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2237-47	6.1	21
137	The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 131-40	6.1	36
136	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 879-87	3.5	26
135	Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. <i>Frontiers in Oncology</i> , 2013 , 3, 259	5.3	61
134	Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. <i>PLoS ONE</i> , 2013 , 8, e72532	3.7	48
133	Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. <i>Cellular and Molecular Life Sciences</i> , 2012 , 69, 1167-78	10.3	33

132	Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. <i>Histochemistry and Cell Biology</i> , 2012 , 137, 195-204	2.4	10
131	A complex of β integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. <i>EMBO Molecular Medicine</i> , 2012 , 4, 1156-75	12	37
130	Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. <i>Neoplasia</i> , 2012 , 14, 846-54	6.4	24
129	Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. <i>Cancer Research</i> , 2012 , 72, 1814-24	10.1	76
128	Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. <i>British Journal of Cancer</i> , 2012 , 107, 360-9	8.7	25
127	Targeting angiogenesis with compounds from the extracellular matrix. <i>International Journal of Biochemistry and Cell Biology</i> , 2011 , 43, 1674-85	5.6	30
126	Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 705-11	7	15
125	Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. <i>British Journal of Dermatology</i> , 2011 , 164, 1061-70	4	21
124	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011 , 3, 480-94	12	58
123	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. <i>Cancer Research</i> , 2011 , 71, 1396-405	10.1	116
122	Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. <i>Journal of Biological Chemistry</i> , 2010 , 285, 8733-42	5.4	61
121	A proteomic approach for the identification of vascular markers of liver metastasis. <i>Cancer Research</i> , 2010 , 70, 309-18	10.1	38
120	Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis. <i>Endocrinology</i> , 2010 , 151, 4643-53	4.8	12
119	The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 184, 2540-8	2.5	54
118	Interleukin-1 β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1 β . <i>European Journal of Cancer</i> , 2010 , 46, 3400-8	7.5	32
117	Angiogenesis inhibitors: implications for combination with conventional therapies. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3921-31	3.3	10
116	A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. <i>Histochemistry and Cell Biology</i> , 2010 , 133, 467-75	2.4	26
115	Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. <i>Clinical and Experimental Metastasis</i> , 2010 , 27, 43-53	4.7	17

114	Combination Therapy with Chemotherapy and VDAs 2010 , 77-93		2
113	Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. <i>Cancer Research</i> , 2009 , 69, 5406-14	10.1	43
112	Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. <i>Journal of Pathology</i> , 2009 , 219, 455-62	9.4	17
111	Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 7906-10	8.3	59
110	Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. <i>European Journal of Cancer</i> , 2009 , 45, 454-60	7.5	19
109	The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. <i>Neoplasia</i> , 2009 , 11, 1155-64	6.4	29
108	In vivo measurement of vascular modulation in experimental tumors using a fluorescent contrast agent. <i>Photochemistry and Photobiology</i> , 2008 , 84, 1249-56	3.6	8
107	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. <i>BMC Genomics</i> , 2008 , 9, 201	4.5	46
106	Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 700-9	5.6	59
105	Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. <i>Molecular Cancer Research</i> , 2008 , 6, 525-34	6.6	63
104	Microtubule Targeting Agents and the Tumor Vasculature 2008 , 519-530		4
103	Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. <i>British Journal of Cancer</i> , 2007 , 97, 888-94	8.7	45
102	Vascular endothelium summary statement III: Cancer prevention and control. <i>Vascular Pharmacology</i> , 2007 , 46, 321-3	5.9	1
101	Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 481-8	9.6	10
100	The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. <i>Clinical Cancer Research</i> , 2006 , 12, 1839-49	12.9	51
99	Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. <i>Neoplasia</i> , 2006 , 8, 96-103	6.4	143
98	Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. <i>European Journal of Cancer</i> , 2006 , 42, 2821-32	7.5	86
97	Stereochemically pure β -trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases. <i>Tetrahedron</i> , 2006 , 62, 10171-10181	2.4	7

96	Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. <i>European Journal of Cancer</i> , 2005 , 41, 470-6	7.5	19
95	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. <i>British Journal of Haematology</i> , 2005 , 128, 310-7	4.5	47
94	In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. <i>Nature Methods</i> , 2005 , 2, 291-8	21.6	124
93	Solution state conformation and degradation of cyclopeptides containing an NGR motif. <i>Journal of Peptide Science</i> , 2005 , 11, 53-9	2.1	6
92	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 715-25	6.1	26
91	Potential antagonism of tubulin-binding anticancer agents in combination therapies. <i>Clinical Cancer Research</i> , 2005 , 11, 2720-6	12.9	22
90	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. <i>Thrombosis and Haemostasis</i> , 2004 , 91, 403-11	7	25
89	Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. <i>Clinical Cancer Research</i> , 2004 , 10, 4813-21	12.9	128
88	Antiangiogenic activity of aplidine, a new agent of marine origin. <i>British Journal of Cancer</i> , 2004 , 90, 2418-24	8.74	76
87	An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. <i>Oncogene</i> , 2004 , 23, 8859-67	9.2	56
86	Synthesis and evaluation of stereopure trifluoromethyl-malic hydroxamates as inhibitors of matrix metalloproteinases. <i>Tetrahedron Letters</i> , 2004 , 45, 1611-1615	2	35
85	Invasion and Metastasis 2004 , 443-461		1
84	Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 111-21	6.1	45
83	IDN 5390: a new concept in taxane development. <i>Anti-Cancer Drugs</i> , 2003 , 14, 255-8	2.4	7
82	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. <i>Blood</i> , 2003 , 102, 4399-406	2.2	70
81	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. <i>Leukemia</i> , 2003 , 17, 52-9	10.7	130
80	Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. <i>American Journal of Pathology</i> , 2003 , 162, 1913-26	5.8	146
79	Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. <i>Cancer Research</i> , 2003 , 63, 1534-7	10.1	84

78	The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. <i>Clinical Cancer Research</i> , 2003 , 9, 3476-85	12.9	38
77	Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. <i>Cancer Research</i> , 2003 , 63, 5224-9	10.1	220
76	Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. <i>American Journal of Pathology</i> , 2002 , 160, 673-80	5.8	433
75	Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. <i>Clinical Cancer Research</i> , 2002 , 8, 1182-8	12.9	41
74	Small molecules in anti-angiogenic therapy. <i>Current Opinion in Investigational Drugs</i> , 2002 , 3, 482-91		1
73	Preclinical development of metalloprotease inhibitors in cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 37, 53-60	7	35
72	p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001 , 20, 7293-300	9.2	45
71	Syngeneic murine metastasis models : b16 melanoma. <i>Methods in Molecular Medicine</i> , 2001 , 58, 223-9		5
70	Anticancer Therapy with Angiogenesis Inhibitors. <i>Tumori</i> , 2001 , 87, 14-16	1.7	
69	Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. <i>International Journal of Cancer</i> , 2001 , 91, 241-7	7.5	27
68	Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat. <i>FASEB Journal</i> , 2000 , 14, 1917-30	0.9	25
67	The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. <i>FASEB Journal</i> , 2000 , 14, 1674-6	0.9	137
66	Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells. <i>Experimental Cell Research</i> , 2000 , 258, 384-94	4.2	41
65	Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. <i>American Journal of Pathology</i> , 2000 , 157, 1703-11	5.8	285
64	Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. <i>Neoplasia</i> , 2000 , 2, 202-7	6.4	17
63	Characterization of novel clonal murine endothelial cell lines with an extended life span. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2000 , 36, 299-308	2.6	5
62	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000 , 95, 2672-2682	2.2	5
61	Adhesion of tumor cells under flow. <i>Methods in Molecular Biology</i> , 1999 , 96, 153-7	1.4	1

60	Adhesion of tumor cells to endothelium under static conditions. <i>Methods in Molecular Biology</i> , 1999 , 96, 147-51	1.4	
59	The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. <i>Annals of Oncology</i> , 1999 , 10, 589-91	10.3	14
58	Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. <i>Clinical and Experimental Metastasis</i> , 1999 , 17, 655-62	4.7	30
57	Mesothelial cells induce the motility of human ovarian carcinoma cells. <i>International Journal of Cancer</i> , 1999 , 80, 303-7	7.5	39
56	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. <i>Journal of Pathology</i> , 1999 , 188, 76-81	9.4	39
55	High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. <i>Annals of Oncology</i> , 1999 , 10, 1233-40	10.3	80
54	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndrome-Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. <i>Blood</i> , 1999 , 94, 1747-1754	2.2	4
53	Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. <i>American Journal of Pathology</i> , 1998 , 152, 1607-16	5.8	33
52	Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. <i>Clinical Cancer Research</i> , 1998 , 4, 1977-83	12.9	81
51	Outbreaks of hyperkeratotic dermatitis of athymic nude mice in northern Italy. <i>Laboratory Animals</i> , 1997 , 31, 206-11	2.6	22
50	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. <i>Leukemia Research</i> , 1997 , 21, 1107-14	2.7	14
49	Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. <i>International Journal of Cancer</i> , 1997 , 70, 72-7	7.5	19
48	IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. <i>International Journal of Cancer</i> , 1996 , 67, 856-63	7.5	33
47	Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. <i>Human Gene Therapy</i> , 1995 , 6, 813-9	4.8	120
46	Matrix metalloproteinase inhibition: a review of anti-tumour activity. <i>Annals of Oncology</i> , 1995 , 6, 967-74	10.3	179
45	Establishment of human acute myelogenous leukemia lines secreting interleukin-1 beta in SCID mice. <i>International Journal of Cancer</i> , 1995 , 61, 280-5	7.5	13
44	Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. <i>Cancer Research</i> , 1995 , 55, 4729-38	10.1	26
43	Cytokines and cell adhesion molecules in tumor-endothelial cell interaction and metastasis. <i>Cell Adhesion and Communication</i> , 1994 , 2, 219-24		14

42	Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. <i>International Journal of Cancer</i> , 1994 , 58, 460-4	7.5	190
41	Enhancement of metastatic potential of murine and human melanoma cells by laminin receptor peptide G: attachment of cancer cells to subendothelial matrix as a pathway for hematogenous metastasis. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 235-40	9.7	41
40	Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. <i>Human Gene Therapy</i> , 1993 , 4, 713-23	4.8	56
39	Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. <i>Annals of Oncology</i> , 1993 , 4, 151-5	10.3	23
38	Comparative study on the metastatic behavior of human tumors in nude, beige/nude/xid and severe combined immunodeficient mice. <i>Invasion & Metastasis</i> , 1993 , 13, 82-91		34
37	Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. <i>Cancer Research</i> , 1993 , 53, 5051-4	10.1	54
36	A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. <i>Journal of Clinical Investigation</i> , 1993 , 92, 2160-7	15.9	89
35	Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. <i>Journal of Clinical Investigation</i> , 1993 , 92, 3038-44	15.9	166
34	Matrigel promotes retinoblastoma cell growth in vitro and in vivo. <i>International Journal of Cancer</i> , 1992 , 52, 234-40	7.5	43
33	Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. <i>Cancer Research</i> , 1992 , 52, 2628-30	10.1	72
32	Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. <i>Exs</i> , 1992 , 61, 210-3		15
31	Organ-specific growth of a murine lymphoma of spontaneous origin in nude mice. <i>Clinical and Experimental Metastasis</i> , 1991 , 9, 485-97	4.7	2
30	An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. <i>Science</i> , 1991 , 251, 1363-6	33.3	111
29	Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. <i>Journal of Cell Biology</i> , 1990 , 111, 765-72	7.3	364
28	Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants. <i>Experimental Cell Research</i> , 1990 , 190, 69-75	4.2	34
27	Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. <i>Cancer Research</i> , 1990 , 50, 4771-5	10.1	151
26	Flavone acetic acid pharmacokinetics in nude mice. <i>Anticancer Research</i> , 1990 , 10, 437-9	2.3	3
25	Tumorigenic and Metastatic Properties of Human Colorectal Carcinomas Transplanted into Nude Mouse 1990 , 311-339		

24	Organ distribution of experimental metastases of a human colorectal carcinoma injected in nude mice. <i>Clinical and Experimental Metastasis</i> , 1989 , 7, 55-68	4.7	36
23	Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. <i>International Journal of Cancer</i> , 1989 , 44, 494-500	7.5	52
22	Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. <i>International Journal of Cancer</i> , 1989 , 44, 707-13	7.5	89
21	Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. <i>British Journal of Cancer</i> , 1988 , 57, 277-80	8.7	30
20	Distribution of mono-, di, and tri-O-acetylated sialic acids in normal and neoplastic colon. <i>Cancer Research</i> , 1988 , 48, 483-9	10.1	35
19	Growth potential of human colorectal carcinomas in nude mice: association with the preoperative serum concentration of carcinoembryonic antigen in patients. <i>Cancer Research</i> , 1988 , 48, 1689-92	10.1	54
18	Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. <i>Cancer Research</i> , 1988 , 48, 2353-60	10.1	27
17	Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells. <i>Journal of Clinical Investigation</i> , 1988 , 82, 1466-70	15.9	114
16	The nude mouse for the study of human colorectal carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 1988 , 233, 39-47	3.6	1
15	Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 1529-35		35
14	Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice. <i>Clinical and Experimental Metastasis</i> , 1987 , 5, 135-46	4.7	27
13	Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. <i>Invasion & Metastasis</i> , 1987 , 7, 16-29		39
12	Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. <i>Journal of Surgical Research</i> , 1986 , 40, 467-74	2.5	7
11	Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. <i>Cancer Research</i> , 1986 , 46, 4109-15	10.1	360
10	Expression of cell surface P-glycoprotein by an adriamycin-resistant murine fibrosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1984 , 13, 145-7	3.5	21
9	Correlation of tumor growth inhibitory activity of macrophages exposed to adriamycin and adriamycin sensitivity of the target tumor cells. <i>Journal of the National Cancer Institute</i> , 1984 , 73, 447-55 ^{9.7}		33
8	Mononuclear phagocyte adherence in the presence of laminin. A possible marker of cellular differentiation. <i>Experimental Cell Research</i> , 1983 , 146, 391-9	4.2	23
7	Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. <i>Cancer Research</i> , 1983 , 43, 2216-22	10.1	27

6	Laminin inhibits the adhesion of a murine tumor of macrophage origin. <i>Experimental Cell Research</i> , 1982 , 140, 315-22	4.2	16
5	Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host. <i>British Journal of Cancer</i> , 1981 , 43, 100-4	8.7	13
4	Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. <i>European Journal of Cancer</i> , 1981 , 17, 71-6		51
3	A murine ovarian tumor with unique metastasizing capacity. <i>European Journal of Cancer</i> , 1981 , 17, 651-8		18
2	Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. <i>International Journal of Cancer</i> , 1980 , 25, 617-20	7.5	54
1	Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. <i>British Journal of Cancer</i> , 1980 , 42, 462-72	8.7	92